Login Register Cart 0
Generic placeholder image

Mini-Reviews in Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 1389-5575
ISSN (Online): 1875-5607

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

MCM3AP-AS1: A LncRNA Participating in the Tumorigenesis of Cancer Through Multiple Pathways

Author(s): Bei Wang, Jinlan Chen, Chen Lin, Ru Liu, Lu Wang and Chengfu Yuan*

Volume 22, Issue 16, 2022

Published on: 31 March, 2022

Page: [2138 - 2145] Pages: 8

DOI: 10.2174/1389557522666220214100718

Price: $65

Abstract

Background: More and more shreds of evidence show that the occurrence and development of tumors are closely related to the abnormal expression of LncRNA. A large number of experiments have found that overexpression or under-expression of MCM3AP-AS1 can affect the occurrence and development of cancer cells in varying degrees, such as proliferation, invasion, and translocation. Besides, MCM3AP-AS1 may become a promising target for many tumor biotherapies. This article reviews the pathophysiological functions and molecular mechanisms of MCM3AP-AS1 in various tumors.

Methods: This paper systematically summarizes the published literatures in PubMed. The molecular mechanism of MCM3AP-AS1 in a variety of tumors is reviewed.

Results: The abnormal expression of MCM3AP-AS1 in different tumors is closely related to tumor proliferation, invasion, and migration. MCM3AP-AS1 mediates or participates in related signaling pathways to regulate the expression of targeted miRNAs and proteins. MCM3AP-AS1 plays a vital role in tumor diagnosis and treatment.

Conclusion: LncRNA MCM3AP-AS1 is a feasible tumor marker and a potential therapeutic target for many kinds of tumors.

Keywords: Long non-coding RNA, MCM3AP-AS1, cancer, biomarkers, prognosis, treatment.

« Previous Next »
Graphical Abstract

[1]
Saliani, M.; Mirzaiebadizi, A.; Mosaddeghzadeh, N.; Ahmadian, M.R. RHO GTPase-related long noncoding RNAs in human cancers. Cancers (Basel), 2021, 13(21), 5386.
[http://dx.doi.org/10.3390/cancers13215386] [PMID: 34771549]
[2]
Stefanicka, P.; Gnojcakova, N.; Kurinec, F.; Profant, M. Incidence and clinical predictors of cystic squamous cell carcinoma metastases in lateral cervical cysts. J. Laryngol. Otol., 2019, 133(5), 430-435.
[http://dx.doi.org/10.1017/S0022215119000823] [PMID: 31006395]
[3]
Murakami, I.; Egawa, N.; Griffin, H.; Yin, W.; Kranjec, C.; Nakahara, T.; Kiyono, T.; Doorbar, J. Roles for E1-independent replication and E6-mediated p53 degradation during low-risk and high-risk human papillomavirus genome maintenance. PLoS Pathog., 2019, 15(5), e1007755.
[http://dx.doi.org/10.1371/journal.ppat.1007755] [PMID: 31083694]
[4]
Lan, L.; Liang, Z.; Zhao, Y.; Mo, Y. LncRNA MCM3AP-AS1 inhibits cell proliferation in cervical squamous cell carcinoma by down-regulating miRNA-93. Biosci. Rep., 2020, 40(2), BSR20193794.
[http://dx.doi.org/10.1042/BSR20193794] [PMID: 31985002]
[5]
Ilic, M.; Ilic, I. Epidemiology of pancreatic cancer. World J. Gastroenterol., 2016, 22(44), 9694-9705.
[http://dx.doi.org/10.3748/wjg.v22.i44.9694] [PMID: 27956793]
[6]
Xia, L.; Song, M.; Sun, M.; Chen, W.; Yang, C. miR-486 promotes capan-2 pancreatic cancer cell proliferation by targeting phosphatase and tensin homolog deleted on chromosome 10 (PTEN). Front. Genet., 2019, 10, 541.
[http://dx.doi.org/10.3389/fgene.2019.00541] [PMID: 31258546]
[7]
Yang, M.; Sun, S.; Guo, Y.; Qin, J.; Liu, G. Long non-coding RNA MCM3AP-AS1 promotes growth and migration through modulating FOXK1 by sponging miR-138-5p in pancreatic cancer. Mol. Med., 2019, 25(1), 55.
[http://dx.doi.org/10.1186/s10020-019-0121-2] [PMID: 31830901]
[8]
Wang, G.; Zhao, D.; Spring, D.J.; DePinho, R.A. Genetics and biology of prostate cancer. Genes Dev., 2018, 32(17-18), 1105-1140.
[http://dx.doi.org/10.1101/gad.315739.118] [PMID: 30181359]
[9]
Joniau, S.; Briganti, A.; Gontero, P.; Gandaglia, G.; Tosco, L.; Fieuws, S.; Tombal, B.; Marchioro, G.; Walz, J.; Kneitz, B.; Bader, P.; Frohneberg, D.; Tizzani, A.; Graefen, M.; van Cangh, P.; Karnes, R.J.; Montorsi, F.; Van Poppel, H.; Spahn, M. Stratification of high-risk prostate cancer into prognostic categories: A European multi-institutional study. Eur. Urol., 2015, 67(1), 157-164.
[http://dx.doi.org/10.1016/j.eururo.2014.01.020] [PMID: 24486307]
[10]
Jia, Z.; Li, W.; Bian, P.; Liu, H.; Pan, D.; Dou, Z. LncRNA MCM3AP-AS1 promotes cell proliferation and invasion through regulating miR-543-3p/SLC39A10/PTEN axis in prostate cancer. OncoTargets Ther., 2020, 13, 9365-9376.
[http://dx.doi.org/10.2147/OTT.S245537] [PMID: 33061424]
[11]
Wu, J.; Lv, Y.; Li, Y.; Jiang, Y.; Wang, L.; Zhang, X.; Sun, M.; Zou, Y.; Xu, J.; Zhang, L. MCM3AP-AS1/miR-876-5p/WNT5A axis regulates the proliferation of prostate cancer cells. Cancer Cell Int., 2020, 20, 307.
[http://dx.doi.org/10.1186/s12935-020-01365-x] [PMID: 32684844]
[12]
Song, M.; Zhong, A.; Yang, J.; He, J.; Cheng, S.; Zeng, J.; Huang, Y.; Pan, Q.; Zhao, J.; Zhou, Z.; Zhu, Q.; Tang, Y.; Chen, H.; Yang, C.; Liu, Y.; Mo, X.; Weng, D.; Xia, J.C. Large-scale analyses identify a cluster of novel long noncoding RNAs as potential competitive endogenous RNAs in progression of hepatocellular carcinoma. Aging (Albany NY), 2019, 11(22), 10422-10453.
[http://dx.doi.org/10.18632/aging.102468] [PMID: 31761783]
[13]
Yan, Y.; Yu, J.; Liu, H.; Guo, S.; Zhang, Y.; Ye, Y.; Xu, L.; Ming, L. Construction of a long non-coding RNA-associated ceRNA network reveals potential prognostic lncRNA biomarkers in hepatocellular carcinoma. Pathol. Res. Pract., 2018, 214(12), 2031-2038.
[http://dx.doi.org/10.1016/j.prp.2018.09.022] [PMID: 30316688]
[14]
Elhendawy, M.; Abdul-Baki, E.A.; Abd-Elsalam, S.; Hagras, M.M.; Zidan, A.A.; Abdel-Naby, A.Y.; Watny, M.; Elkabash, I.A.; Salem, M.L.; Elshanshoury, M.; Soliman, S.; Abdou, S. MicroRNA signature in hepatocellular carcinoma patients: Identification of potential markers. Mol. Biol. Rep., 2020, 47(7), 4945-4953.
[http://dx.doi.org/10.1007/s11033-020-05521-4] [PMID: 32430845]
[15]
Abdel Ghafar, M.T.; Morad, M.A.; El-Zamarany, E.A.; Ziada, D.; Soliman, H.; Abd-Elsalam, S.; Salama, M. Autologous dendritic cells pulsed with lysate from an allogeneic hepatic cancer cell line as a treatment for patients with advanced hepatocellular carcinoma: A pilot study. Int. Immunopharmacol., 2020, 82, 106375.
[http://dx.doi.org/10.1016/j.intimp.2020.106375] [PMID: 32169808]
[16]
Watany, M.; Badawi, R.; Elkhalawany, W.; Abd-Elsalam, S. Study of dickkopf-1 (DKK-1) gene expression in hepatocellular carcinoma patients. J. Clin. Diagn. Res., 2017, 11(2), OC32-OC34.
[http://dx.doi.org/10.7860/JCDR/2017/23095.9450] [PMID: 28384913]
[17]
Wang, Y.; Yang, L.; Chen, T.; Liu, X.; Guo, Y.; Zhu, Q.; Tong, X.; Yang, W.; Xu, Q.; Huang, D.; Tu, K. A novel lncRNA MCM3AP-AS1 promotes the growth of hepatocellular carcinoma by targeting miR-194-5p/FOXA1 axis. Mol. Cancer, 2019, 18(1), 28.
[http://dx.doi.org/10.1186/s12943-019-0957-7] [PMID: 30782188]
[18]
Zhang, H.; Luo, C.; Zhang, G. LncRNA MCM3AP-AS1 regulates epidermal growth factor receptor and autophagy to promote hepatocellular carcinoma metastasis by interacting with miR-455. DNA Cell Biol., 2019, 38(8), 857-864.
[http://dx.doi.org/10.1089/dna.2019.4770] [PMID: 31237446]
[19]
Riahi, A.; Hosseinpour-Feizi, M.; Rajabi, A.; Akbarzadeh, M.; Montazeri, V.; Safaralizadeh, R. Overexpression of long noncoding RNA MCM3AP-AS1 in breast cancer tissues compared to adjacent non-tumour tissues Br. J. Biomed. Sci., 2020, 1-5.
[PMID: 32678686]
[20]
Sun, Y.S.; Zhao, Z.; Yang, Z.N.; Xu, F.; Lu, H.J.; Zhu, Z.Y.; Shi, W.; Jiang, J.; Yao, P.P.; Zhu, H.P. Risk factors and preventions of breast cancer. Int. J. Biol. Sci., 2017, 13(11), 1387-1397.
[http://dx.doi.org/10.7150/ijbs.21635] [PMID: 29209143]
[21]
Chen, Q.; Xu, H.; Zhu, J.; Feng, K.; Hu, C. LncRNA MCM3AP-AS1 promotes breast cancer progression via modulating miR-28- 5p/CENPF axis. Biomed. Pharmacother., 2020, 128, 110289.
[22]
Song, Z.; Wu, Y.; Yang, J.; Yang, D.; Fang, X. Progress in the treatment of advanced gastric cancer. Tumour Biol., 2017, 39(7), 1010428317714626.
[http://dx.doi.org/10.1177/1010428317714626] [PMID: 28671042]
[23]
Wang, H.; Xu, T.; Wu, L.; Xu, H.L.; Liu, R.M. Molecular mechanisms of MCM3AP-AS1 targeted the regulation of miR-708-5p on cell proliferation and apoptosis in gastric cancer cells Eur. Rev. Med. Pharmacol. Sci., 2020, 24(5), 2452-2461.
[PMID: 32196596]
[24]
Heinimann, K. Hereditary colorectal cancer: Clinics, diagnostics and management. Ther. Umsch., 2018, 75(10), 601-606.
[http://dx.doi.org/10.1024/0040-5930/a001046] [PMID: 31232663]
[25]
Ma, X.; Luo, J.; Zhang, Y.; Sun, D.; Lin, Y. LncRNA MCM3AP-AS1 upregulates CDK4 by sponging miR-545 to suppress G1 arrest in colorectal cancer. Cancer Manag. Res., 2020, 12, 8117-8124.
[http://dx.doi.org/10.2147/CMAR.S247330] [PMID: 32982409]
[26]
Dai, W.; Zeng, W.; Lee, D. lncRNA MCM3AP-AS1 inhibits the progression of colorectal cancer via the miR-19a-3p/FOXF2 axis. J. Gene Med., 2021, 23(3), e3306.
[http://dx.doi.org/10.1002/jgm.3306] [PMID: 33450091]
[27]
Eisenhauer, E.A. Real-world evidence in the treatment of ovarian cancer. Ann. Oncol, 2017, 28(suppl_8), viii61-viii5.
[http://dx.doi.org/10.1093/annonc/mdx443]
[28]
Wen, J.; Han, S.; Cui, M.; Wang, Y. Long non-coding RNA MCM3AP-AS1 drives ovarian cancer progression via the microRNA-143-3p/TAK1 axis. Oncol. Rep., 2020, 44(4), 1375-1384.
[http://dx.doi.org/10.3892/or.2020.7694] [PMID: 32945454]
[29]
Bade, B.C.; Dela Cruz, C.S. Lung cancer 2020: Epidemiology, etiology, and prevention. Clin. Chest Med., 2020, 41(1), 1-24.
[http://dx.doi.org/10.1016/j.ccm.2019.10.001] [PMID: 32008623]
[30]
Evans, M. Lung cancer: Needs assessment, treatment and therapies. Br. J. Nurs., 2013, 22(17), S15-S16.
[http://dx.doi.org/10.12968/bjon.2013.22.Sup17.S15]
[31]
Li, X.; Yu, M.; Yang, C. YY1-mediated overexpression of long noncoding RNA MCM3AP-AS1 accelerates angiogenesis and progression in lung cancer by targeting miR-340-5p/KPNA4 axis. J. Cell. Biochem., 2020, 121(3), 2258-2267.
[http://dx.doi.org/10.1002/jcb.29448] [PMID: 31693222]
[32]
Campos, B.; Olsen, L.R.; Urup, T.; Poulsen, H.S. A comprehensive profile of recurrent glioblastoma. Oncogene, 2016, 35(45), 5819-5825.
[http://dx.doi.org/10.1038/onc.2016.85] [PMID: 27041580]
[33]
Yang, C.; Zheng, J.; Xue, Y.; Yu, H.; Liu, X.; Ma, J.; Liu, L.; Wang, P.; Li, Z.; Cai, H.; Liu, Y. The effect of MCM3AP-AS1/miR-211/KLF5/AGGF1 axis regulating glioblastoma angiogenesis. Front. Mol. Neurosci., 2018, 10, 437.
[http://dx.doi.org/10.3389/fnmol.2017.00437] [PMID: 29375300]
[34]
Panarese, I.; Aquino, G.; Ronchi, A.; Longo, F.; Montella, M.; Cozzolino, I.; Roccuzzo, G.; Colella, G.; Caraglia, M.; Franco, R. Oral and oropharyngeal squamous cell carcinoma: prognostic and predictive parameters in the etiopathogenetic route. Expert Rev. Anticancer Ther., 2019, 19(2), 105-119.
[http://dx.doi.org/10.1080/14737140.2019.1561288] [PMID: 30582397]
[35]
Hou, C.; Wang, X.; Du, B. lncRNA MCM3AP-AS1 promotes the development of oral squamous cell carcinoma by inhibiting miR-363-5p. Exp. Ther. Med., 2020, 20(2), 978-984.
[http://dx.doi.org/10.3892/etm.2020.8738] [PMID: 32742341]
[36]
Li, H.; Jiang, J. LncRNA MCM3AP-AS1 promotes proliferation, migration and invasion of oral squamous cell carcinoma cells via regulating miR-204-5p/FOXC1 Investig. Med., 2020, 68(7), 1282-1288.
[37]
Lee, H.M.; Okuda, K.S.; González, F.E.; Patel, V. Current perspectives on nasopharyngeal carcinoma. Adv. Exp. Med. Biol., 2019, 1164, 11-34.
[http://dx.doi.org/10.1007/978-3-030-22254-3_2] [PMID: 31576537]
[38]
Sun, X.; Su, S.; Chen, C.; Han, F.; Zhao, C.; Xiao, W.; Deng, X.; Huang, S.; Lin, C.; Lu, T. Long-term outcomes of intensity-modulated radiotherapy for 868 patients with nasopharyngeal carcinoma: An analysis of survival and treatment toxicities. Radiother. Oncol., 2014, 110(3), 398-403.
[http://dx.doi.org/10.1016/j.radonc.2013.10.020] [PMID: 24231245]
[39]
Sun, P.; Feng, Y.; Guo, H.; Li, R.; Yu, P.; Zhou, X.; Pan, Z.; Liang, Y.; Yu, B.; Zheng, Y.; Shi, Y.; Wen, L.; Wei, M.; Chen, Y. MiR-34a inhibits cell proliferation and induces apoptosis in human nasopharyngeal carcinoma by targeting lncRNA MCM3AP-AS1. Cancer Manag. Res., 2020, 12, 4799-4806.
[http://dx.doi.org/10.2147/CMAR.S245520] [PMID: 32606969]
[40]
Abdullah, M.I.; Junit, S.M.; Ng, K.L.; Jayapalan, J.J.; Karikalan, B.; Hashim, O.H. Papillary thyroid cancer: Genetic alterations and molecular biomarker investigations. Int. J. Med. Sci., 2019, 16(3), 450-460.
[http://dx.doi.org/10.7150/ijms.29935] [PMID: 30911279]
[41]
Liang, M.; Jia, J.; Chen, L.; Wei, B.; Guan, Q.; Ding, Z.; Yu, J.; Pang, R.; He, G. LncRNA MCM3AP-AS1 promotes proliferation and invasion through regulating miR-211-5p/SPARC axis in papillary thyroid cancer. Endocrine, 2019, 65(2), 318-326.
[http://dx.doi.org/10.1007/s12020-019-01939-4] [PMID: 31030335]
[42]
Wolf, M.M.; Kimryn Rathmell, W.; Beckermann, K.E. Modeling clear cell renal cell carcinoma and therapeutic implications. Oncogene, 2020, 39(17), 3413-3426.
[http://dx.doi.org/10.1038/s41388-020-1234-3] [PMID: 32123314]
[43]
Qiu, L.; Ma, Y.; Yang, Y.; Ren, X.; Wang, D.; Jia, X. Pro-angiogenic and pro-inflammatory regulation by lncRNA MCM3AP-AS1-mediated upregulation of DPP4 in clear cell renal cell carcinoma. Front. Oncol., 2020, 10, 705.
[http://dx.doi.org/10.3389/fonc.2020.00705] [PMID: 32714856]
[44]
Ferry, J.A. Burkitt’s lymphoma: Clinicopathologic features and differential diagnosis. Oncologist, 2006, 11(4), 375-383.
[http://dx.doi.org/10.1634/theoncologist.11-4-375] [PMID: 16614233]
[45]
Guo, C.; Gong, M.; Li, Z. Knockdown of lncRNA MCM3AP-AS1 attenuates chemoresistance of burkitt lymphoma to doxorubicin treatment via targeting the miR-15a/EIF4E Axis. Cancer Manag. Res., 2020, 12, 5845-5855.
[http://dx.doi.org/10.2147/CMAR.S248698] [PMID: 32765087]

Rights & Permissions Print Cite
Article Metrics
28
1
© 2024 Bentham Science Publishers | Privacy Policy